TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15949921

Group type: EXPERIMENTAL
Intervention: Deramciclane 60 mg/day
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Deramciclane 30 mg/day
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Deramciclane 10 mg/day
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 12898851

Group type: EXPERIMENTAL
Intervention: Asymptomatic patients on CAPD with urinary tract infections (UTI)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Diabetic patients on CAPD
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-infected patients on CAPD
Number of subjects: 43
Study: 10396388

Group type: EXPERIMENTAL
Intervention: Pre-operative assessment by a trained ophthalmic nurse at the peripheral clinic
Number of subjects: 49

Group type: COMPARATOR
Intervention: Separate appointment for pre-operative assessment at the main hospital
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nurse-led pre-operative assessment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 7552478

Group type: EXPERIMENTAL
Intervention: CD4‐IgG 30, 100, or 300 micrograms/kg weekly; 1,000 micrograms/kg once, twice, or three times per week; or 3,000 micrograms/kg twice weekly
Number of subjects: 22
Study: 1705151

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 7040492

Group type: EXPERIMENTAL
Intervention: Bumetanide (1 to 10 mg/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Furosemide (40 to 400 mg/day)
Number of subjects: 43
Study: 31003681

Group type: EXPERIMENTAL
Intervention: Gua Sha therapy (12 sessions, one session per week)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Gua Sha therapy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 119
Study: 27552000

Group type: EXPERIMENTAL
Intervention: Combined treatment based on TNF alpha inhibitors and low‐carbohydrates calorie‐restricted diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: TNF‐alpha inhibitors
Number of subjects: 20
Study: 26686262

Group type: EXPERIMENTAL
Intervention: Text message reminders (daily tailored messages for 4 days)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard discharge instructions
Number of subjects: 92
Study: 25300981

Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 404

Group type: COMPARATOR
Intervention: Vertebroplasty
Number of subjects: 404
Study: 21982723

Group type: EXPERIMENTAL
Intervention: Sublingual testosterone 0.25 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sublingual testosterone 0.50 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sublingual testosterone 0.75 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sublingual testosterone (all doses)
Number of subjects: 16
Study: 19886836

Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control (single-dose nevirapine)
Number of subjects: 328
Study: 16768082

Group type: EXPERIMENTAL
Intervention: Communication of the quality of life findings to the coordinating physician
Number of subjects: 200

Group type: COMPARATOR
Intervention: No communication (Control)
Number of subjects: 200
Study: 12838187

Group type: EXPERIMENTAL
Intervention: IVMP plus ASA/IVIG
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASA/IVIG
Number of subjects: 0
Study: 11113749

Group type: EXPERIMENTAL
Intervention: Neoadjuvant luteinizing hormone-releasing hormone-analogue treatment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment
Number of subjects: 103
Study: 9007183

Group type: EXPERIMENTAL
Intervention: Modified technique of ultrafiltration (MUF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (CUF)
Number of subjects: 80
Study: 1354948

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (0.15 mg/kg x 2)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: IV salbutamol (5 micrograms/kg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Aminophylline (3 mg/kg) infusion
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Patients with an increase in PEF > 10% of the predicted value (n = 14)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Inhaled vs IV salbutamol
Number of subjects: 101
Study: 6231339

Group type: EXPERIMENTAL
Intervention: Marcaine and fentanyl mixture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Marcaine alone
Number of subjects: 60
Study: 30612266

Group type: EXPERIMENTAL
Intervention: Group singing therapy (once a week for 24 sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine health education (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group singing therapy
Number of subjects: 60
Study: 28479233

Group type: EXPERIMENTAL
Intervention: Epirubicin, cyclophosphamide, paclitaxel, and gemcitabine (gemcitabine group; n=1576)
Number of subjects: 3152

Group type: COMPARATOR
Intervention: Epirubicin, cyclophosphamide, and paclitaxel (control group; n=1576)
Number of subjects: 3152

Group type: EXPERIMENTAL
Intervention: Epirubicin, cyclophosphamide, paclitaxel, and gemcitabine (gemcitabine group)
Number of subjects: 3152

Group type: COMPARATOR
Intervention: Epirubicin, cyclophosphamide, and paclitaxel (control group)
Number of subjects: 3152
Study: 25925312

Group type: EXPERIMENTAL
Intervention: Di-Tan decoction (DTD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23078573

Group type: EXPERIMENTAL
Intervention: Emdogain® with open flap debridement and EDTA 24% (PrefGel®)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Open flap debridement with EDTA 24% (PrefGel®)
Number of subjects: 15
Study: 21528591

Group type: EXPERIMENTAL
Intervention: Selective filiform needle group (group A)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Selective acupuncture + moxibustion group (group B)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Selective acupuncture + electroacupuncture (group C)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Selective acupuncture + line‐up needling on muscle region of meridian group (group D)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Non‐selective filiform needle group (group E)
Number of subjects: 900
Study: 19935479

Group type: EXPERIMENTAL
Intervention: Psychosocial support from the School Project of Humanitarian Association of 'Prijateljice'
Number of subjects: 408

Group type: COMPARATOR
Intervention: No psychosocial assistance (Control)
Number of subjects: 408
Study: 17123742

Group type: EXPERIMENTAL
Intervention: 10mg S-Citalopram
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 20mg S-Citalopram
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15209288

Group type: EXPERIMENTAL
Intervention: Single nostril stimulation with 7 different concentrations of 4 specific odorants (2 pleasant and 2 unpleasant)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Electrodermal response to confirm the first psychophysic measure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bilateral recordings of electrodermal activity (EDA) with unilateral stimulation
Number of subjects: 30
Study: 11150274

Group type: EXPERIMENTAL
Intervention: Mechanical epithelial debridement
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laser-scrape epithelial removal
Number of subjects: 20
Study: 9693398

Group type: EXPERIMENTAL
Intervention: 75 microgram desogestrel (DSG)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 30 microgram levonorgestrel (LNG)
Number of subjects: 78
Study: 8156515

Group type: EXPERIMENTAL
Intervention: Fluconazole (FLU) 400 mg daily
Number of subjects: 77

Group type: COMPARATOR
Intervention: Amphotericin B (AMB) 0.5 mg/kg three times weekly
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Fluconazole (FLU)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Amphotericin B (AMB)
Number of subjects: 77
Study: 3073045

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (Rocephin), administered once daily for a mean duration of 9.9 days.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ampicillin or ampicillin plus chloramphenicol, administered in 4 doses/day for a mean duration of 12.3 days.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ampicillin or ampicillin plus chloramphenicol
Number of subjects: 26
Study: 29701038

Group type: EXPERIMENTAL
Intervention: Dynamic scalp acupuncture combined with PNF therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with PNF therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Simple PNF therapy
Number of subjects: 90
Study: 27655261

Group type: EXPERIMENTAL
Intervention: Financial incentives for adherence to antipsychotic depot medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 0
Study: 25701449

Group type: EXPERIMENTAL
Intervention: Animal-Assisted Therapy (AAT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard treatment protocol
Number of subjects: 34
Study: 23129179

Group type: EXPERIMENTAL
Intervention: Orally inhaled allergen
Number of subjects: 5

Group type: COMPARATOR
Intervention: Orally inhaled diluent placebo
Number of subjects: 5
Study: 20872709

Group type: EXPERIMENTAL
Intervention: LAM+ADV
Number of subjects: 92

Group type: COMPARATOR
Intervention: ETV
Number of subjects: 92
Study: 18845973

Group type: EXPERIMENTAL
Intervention: H1‐receptor antagonist (blockade)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no H1‐receptor antagonist)
Number of subjects: 15
Study: 17015810

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs) other than clozapine
Number of subjects: 227

Group type: COMPARATOR
Intervention: First-generation antipsychotics (FGAs)
Number of subjects: 227
Study: 15070084

Group type: EXPERIMENTAL
Intervention: Congruent delay between cue and outcome
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incongruent delay between cue and outcome
Number of subjects: 0
Study: 10669862

Group type: EXPERIMENTAL
Intervention: P34/Gly m Bd 30K protein
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Single-site amino acid substitution of the 5 immunodominant epitopes with alanine
Number of subjects: 6
Study: 9322562

Group type: EXPERIMENTAL
Intervention: Diet + Exercise (DE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diet-Only (D-2092)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diet-Only (D-2929)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups (DE, D-2092, D-2929)
Number of subjects: 40
Study: 8228631

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3320488

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 0
Study: 28737464

Group type: EXPERIMENTAL
Intervention: Continuous aerobic exercise (35 minutes at 85-90% HRAT)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Interval aerobic exercise (45 minutes with intensity 85-90% HRAT and recovery under 85% HRAT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Continuous aerobic exercise
Number of subjects: 14

Group type: COMPARATOR
Intervention: Interval aerobic exercise
Number of subjects: 14
Study: 27604388

Group type: EXPERIMENTAL
Intervention: 30 mg/kg intravenous methylprednisolone
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 30 mg/kg intravenous methylprednisolone after anaesthesia induction
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 30 mg/kg methylprednisolone in the cardiopulmonary bypass prime solution
Number of subjects: 85
Study: 24929058

Group type: EXPERIMENTAL
Intervention: 250 mg of methylprednisolone intravenously (IV) four times a day for 24 hours after the operation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no methylprednisolone)
Number of subjects: 40
Study: 23250605

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa (nakom) treatment in Group 1 (230 patients not previously treated with levodopa)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa (nakom) treatment in Group 2 (262 patients treated with levodopa/carbidopa needing higher doses)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa (nakom) treatment in Group 3 (271 patients treated earlier with other levodopa preparations)
Number of subjects: 763
Study: 19114414

Group type: EXPERIMENTAL
Intervention: 600 mg valerian (Valeriana officinalis, n = 7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 15
Study: 17894655

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a 360 microg/week
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a 270 microg/week
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a 180 microg/week
Number of subjects: 75
Study: 15516023

Group type: COMPARATOR
Intervention: Trospium chloride oral tablet (20 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Eudragit-coated tablets dissolving at pH 6.0 (local administration into the small intestine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rectal administration via mini enema (local administration into the large intestine)
Number of subjects: 8
Study: 11782642

Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (HEX) at 80% of 1-RM for 8 repetitions, 3 times per week for 24 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise (LEX) at 50% of 1-RM for 13 repetitions, 3 times per week for 24 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 62
Study: 9828987

Group type: EXPERIMENTAL
Intervention: Graded exercise and 20 mg fluoxetine
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Graded exercise and placebo drug
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Appointments only and 20 mg fluoxetine
Number of subjects: 136

Group type: COMPARATOR
Intervention: Appointments and placebo drug
Number of subjects: 136
Study: 8138437

Group type: EXPERIMENTAL
Intervention: Hypofractionated regimen (2.35 Gy, 4 days-a-week)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Conventional radiotherapy (2 Gy, 5 days-a-week)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Type of surgery performed
Number of subjects: 204
Study: 2132407

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 24
Study: 1265295

Group type: EXPERIMENTAL
Intervention: Intrauterine administration of 5 mg PGF2alpha
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 100
Study: 31087123

Group type: EXPERIMENTAL
Intervention: CIDEX® OPA
Number of subjects: 88

Group type: COMPARATOR
Intervention: STERRAD NX
Number of subjects: 88
Study: 30094893

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 74
Study: 28694204

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: Education classes and social calls (attention control)
Number of subjects: 320
Study: 25846982

Group type: EXPERIMENTAL
Intervention: Web-based self-help
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: In-person behavior therapy
Number of subjects: 53
Study: 24308187

Group type: EXPERIMENTAL
Intervention: Sanyinjiao (SP 6) group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Xuanzhong (GB 39) group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Non‐acupoint group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 21257798

Group type: COMPARATOR
Intervention: INCB018424 phosphate, 5 to 200 mg single ascending doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: INCB018424 phosphate, 25 mg bid and 100 mg qd
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fat meal effect on INCB018424
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacodynamics of INCB018424
Number of subjects: 0
Study: 20016232

Group type: EXPERIMENTAL
Intervention: Biweekly CHOP (6-8 cycles every 2 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard CHOP (every 3 weeks)
Number of subjects: 130
Study: 15828875

Group type: EXPERIMENTAL
Intervention: Frequent ventricular pacing (51-100% cumulative pacing)
Number of subjects: 742

Group type: COMPARATOR
Intervention: Infrequent ventricular pacing (0-50% cumulative pacing)
Number of subjects: 742
Study: 12874502

Group type: EXPERIMENTAL
Intervention: 10 mg dose of methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10191892

Group type: EXPERIMENTAL
Intervention: Desmopressin (20 micrograms intranasally at bedtime, increased to 40 micrograms after 2 weeks if partial result was obtained)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Alarm (pad‐bell device)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Alarm
Number of subjects: 135
Study: 7754799

Group type: COMPARATOR
Intervention: 1 alpha‐(OH)D3 alone (Group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1 alpha‐(OH)D3 plus 24,25‐(OH)2D3 (Group B)
Number of subjects: 24
Study: 2268938

Group type: EXPERIMENTAL
Intervention: Acupuncture and routine drugs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine drugs only
Number of subjects: 40
Study: 6992827

Group type: EXPERIMENTAL
Intervention: Immunotherapy consisting of intradermal BCG plus allogeneic cells
Number of subjects: 41

Group type: COMPARATOR
Intervention: No maintenance treatment
Number of subjects: 41
Study: 29519541

Group type: EXPERIMENTAL
Intervention: Caffeine (20 mg/kg loading dose followed by 5 mg/kg/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo (blinded loading dose of caffeine)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 28837207

Group type: EXPERIMENTAL
Intervention: Apixaban (10 mg twice daily for 7 days followed by 5 mg twice daily thereafter)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Dalteparin (200 IU/Kg daily for 30 days followed by 150 IU/kg daily thereafter)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 300

Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 300
Study: 26623651

Group type: EXPERIMENTAL
Intervention: Tilt table therapy with integrated stepping device (Erigo)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional tilt table therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both interventions (Tilt table with integrated stepping device and Conventional tilt table therapy)
Number of subjects: 50
Study: 24043276

Group type: EXPERIMENTAL
Intervention: Intervention (18 1-hour home-based therapy sessions)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 200
Study: 21373908

Group type: EXPERIMENTAL
Intervention: Gap-balancing technique (GG)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Measured resection technique (MG)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both techniques (GG and MG)
Number of subjects: 67
Study: 18167170

Group type: EXPERIMENTAL
Intervention: 0.1 to 0.8 % (w/w) MSG in clear soup
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.25 % (w/w) IMP-5 added to MSG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MSG +/‐ 0.25 % IMP-5
Number of subjects: 60
Study: 16406273

Group type: EXPERIMENTAL
Intervention: Pethidine (100 mg)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study: 14550823

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 34
Study: 10898675

Group type: EXPERIMENTAL
Intervention: Abacavir 100 mg BID
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Abacavir 300 mg BID
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Abacavir 600 mg BID
Number of subjects: 41
Study: 8792786

Group type: EXPERIMENTAL
Intervention: Quality assurance experimental interventions
Number of subjects: 0
Study: 1473726

Group type: EXPERIMENTAL
Intervention: Regression model to predict quantiles of narrow sense individual and family mean heritabilities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulations of balanced sib analysis trials in randomized complete block designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estimates of expected heritability and Taylor approximation of standard error of heritability
Number of subjects: 0
Study: 6513774

Group type: EXPERIMENTAL
Intervention: 6-min 'all-out' test (6M-AO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Progressive incremental test (PI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both tests (6M-AO and PI)
Number of subjects: 12
Study: 30112318

Group type: EXPERIMENTAL
Intervention: Educational package
Number of subjects: 60
Study: 27543533

Group type: EXPERIMENTAL
Intervention: PecS II block with ropivacaine 0.5%, 25 ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: TPVB with ropivacaine 0.5%, 25 ml
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PecS II block
Number of subjects: 40

Group type: COMPARATOR
Intervention: TPVB
Number of subjects: 40
Study: 24450857

Group type: EXPERIMENTAL
Intervention: Idelalisib (150 mg) plus rituximab
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Rituximab plus Idelalisib
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo plus rituximab
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Idelalisib plus rituximab
Number of subjects: 220
Study: 22847288

Group type: EXPERIMENTAL
Intervention: Music group (n = 83) listened to music 7 times for 30 minutes during the first 3 postoperative days
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (n = 85) did not listen to music
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Music group (n = 83)
Number of subjects: 168
Study: 20339099

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg/day (LOS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg/day (LOS) plus Hydrochlorothiazide 25 mg/day (LOS/HCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0